Schrödinger Announces Strategic Agreement With Bristol Myers Squibb To Deploy Bunsen Agentic AI Co-Scientist At Scale Across Its Research Organization

Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%

Bristol Myers Squibb reports positive Phase 3 trial data, showing ZENBEXUS cuts the multiple myeloma progression risk by 51%.

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold.

Bristol Myers Squibb Says Zenbexus Combo Shows 51% Lower Risk Of Myeloma Progression Or Death vs. Standard Of Care In Phase 3

Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Lowers Price Target to $53

Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and lowers the price target from $59 to $53.

Global Drug Discovery AI Tools Market - Strategic Forecast 2026-2032 | Generative AI, Cloud Platforms, and Integrated R&D Workflows Create New Growth Opportunities

A comprehensive market research report examines the growing role of AI tools in drug discovery, covering applications in target identification, molecular design, and preclinical testing. The market is shifting from isolated computational experiments toward integrated workflows combining data systems and laboratory validation. Success depends on data quality, model interpretability, regulatory compliance, and multidisciplinary expertise across biology, chemistry, and data science.

'HHS launches project to speed up clinical trials' - Axios